441 related articles for article (PubMed ID: 32487481)
1. Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches.
Glass DS; Grossfeld D; Renna HA; Agarwala P; Spiegler P; Kasselman LJ; Glass AD; DeLeon J; Reiss AB
Respir Investig; 2020 Sep; 58(5):320-335. PubMed ID: 32487481
[TBL] [Abstract][Full Text] [Related]
2. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
3. Practical management of Idiopathic Pulmonary Fibrosis.
Kishaba T
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):90-8. PubMed ID: 26278687
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic pulmonary fibrosis.
Koudstaal T; Wijsenbeek MS
Presse Med; 2023 Sep; 52(3):104166. PubMed ID: 37156412
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic advances in idiopathic pulmonary fibrosis.
Fraser E; Hoyles RK
Clin Med (Lond); 2016 Feb; 16(1):42-51. PubMed ID: 26833513
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic pulmonary fibrosis: pathogenesis and management.
Sgalla G; Iovene B; Calvello M; Ori M; Varone F; Richeldi L
Respir Res; 2018 Feb; 19(1):32. PubMed ID: 29471816
[TBL] [Abstract][Full Text] [Related]
7. The diagnosis and treatment of idiopathic pulmonary fibrosis.
Behr J
Dtsch Arztebl Int; 2013 Dec; 110(51-52):875-81. PubMed ID: 24529303
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment.
Martinez FJ; Flaherty KR
Chest; 2017 May; 151(5):1173-1174. PubMed ID: 28483105
[TBL] [Abstract][Full Text] [Related]
9. Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.
Jo HE; Randhawa S; Corte TJ; Moodley Y
Drugs Aging; 2016 May; 33(5):321-34. PubMed ID: 27083934
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
11. Current approaches to the management of idiopathic pulmonary fibrosis.
Raghu G; Richeldi L
Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
13. [Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment].
Behr J
Dtsch Med Wochenschr; 2012 Mar; 137(12):601-4. PubMed ID: 22415624
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic pulmonary fibrosis: evolving concepts.
Ryu JH; Moua T; Daniels CE; Hartman TE; Yi ES; Utz JP; Limper AH
Mayo Clin Proc; 2014 Aug; 89(8):1130-42. PubMed ID: 24867394
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
16. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells.
Molina-Molina M; Machahua-Huamani C; Vicens-Zygmunt V; Llatjós R; Escobar I; Sala-Llinas E; Luburich-Hernaiz P; Dorca J; Montes-Worboys A
BMC Pulm Med; 2018 Apr; 18(1):63. PubMed ID: 29703175
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone.
Varone F; Mastrobattista A; Franchi P; Viglietta L; Poletti V; Tomassetti S; Dubini A; Tagliaboschi L; Calandriello L; Farchione A; Larici AR
Clin Respir J; 2018 Jan; 12(1):347-351. PubMed ID: 27322356
[TBL] [Abstract][Full Text] [Related]
18. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
19. Novel mechanisms and treatment of idiopathic pulmonary fibrosis.
Elmufdi F; Henke CA; Perlman DM; Tomic R; Kim HJ
Discov Med; 2015 Sep; 20(109):145-53. PubMed ID: 26463096
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic pulmonary fibrosis: the turning point is now!
Funke M; Geiser T
Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
